Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

he AEGIS open-label clinical study, investigators examined the safety and efficacy of Soliris in Japanese patients with PNH relative to the SHEPHERD and TRIUMPH studies. The primary endpoints of the study were reduction of hemolysis and safety following 12 weeks of Soliris treatment. The AEGIS study included 29 patients at nine institutions with minimal transfusion requirements (one or more transfusion episodes in the preceding two years) and permitted enrollment of patients with significant thrombocytopenia (platelet counts greater than or equal to 30x10(9)/L). Forty-five percent of the AEGIS patients had a history of aplastic anemia or myelodysplastic syndromes. Patients were dosed in accordance with the Soliris product labels approved in the United States and European Union in 2007.

Key clinical efficacy data from the AEGIS trial presented at the ASH meeting included:

    -- Hemolysis, the primary trial endpoint, was rapidly and significantly
       reduced with Soliris treatment. A standard measure of hemolysis,
       lactate dehydrogenase (LDH), decreased 86 percent from a median of
       1,814 U/L at baseline to a median of 244 U/L following 12 weeks of
       treatment (P<0.001; normal range 103-223 U/L).
    -- Control of hemolysis resulted in an improvement in anemia as indicated
       by a reduction in packed red blood cell (PRBC) transfusion
       requirements. Transfusions were reduced 71 percent from a mean (SE) of
       5.2 (+/-1.04) PRBC units/patient during the 12-week pre-treatment
       period to 1.5 (+/-0.67) units/patient following 12 weeks of Soliris
       treatment (P<0.001 for the pre-specified median change). Transfusion
       independence was achieved in 67 percent (14/21) of patients who were
       transfusion dependent prior to treatment (P<0.001).
    -- The improvement in anemia with Soliris treatment was also indicated by
       increased hemoglobin levels. Hemoglobi
'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
(Date:7/25/2014)...  AMETEK, Inc. (NYSE: AME ) today ... as Vice President and General Manager, Engineered Medical Components, ... "I am pleased that Kurt has joined ... experience, especially in the medical device industry, and we ... growth and success of our medical components businesses," commented ...
Breaking Medicine Technology:Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Intensive Blood Sugar Control Are, Not Statistically Significant but Show Favorable Trend ... ... Events, SAN FRANCISCO, June 8 Findings from the Veterans,Affairs Diabetes ... diabetes patients were,released today at the 68th Scientific Sessions of the American ...
... the ... Diabetes Association, SAN FRANCISCO, June 7 Amylin Pharmaceuticals,Inc. (Nasdaq: ... and Alkermes, Inc.,(Nasdaq: ALKS ) announced results from a 30-week ... formulation of,exenatide, to BYETTA(R) (exenatide) injection. Type 2 diabetes patients,treated with ...
Cached Medicine Technology:Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 2Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 3Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 2Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 3Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 5Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 6Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 7Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 8
(Date:7/25/2014)... 25, 2014 As reported by People Magazine ... After Jersey Shore and Getting Sober (7/15), one of ... Shore, has spoken out to the public about his personal ... show, The Situation admits that moving on with his life ... drugs, and other drugs in 2012 and even spent some ...
(Date:7/25/2014)... News) -- The human brain can preserve oxygen to ... study finds. Although dehydration significantly reduces blood ... that the brain compensates by increasing the amount of ... has helped us understand a lot more about how ... conditions," study first author Steven Trangmar, a researcher at ...
(Date:7/25/2014)... July 25, 2014 Art of Facial Surgery ... to those in Toronto who are looking for minor touch-ups ... study done by the American Academy of Facial Plastic and ... interest in facial plastic surgery showed a surprising increase between ... 10 percent, while hair transplants increased by 7 percent and ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... 2014(BRONX, NY)A study involving nearly 27,000 older adults on ... criteria for pre-dementia based on a simple test that ... cognitive complaints. People who tested positive for pre-dementia were ... 12 years. The study, led by scientists at ... and Montefiore Medical Center , was published online ...
Breaking Medicine News(10 mins):Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4
... on sodas, other sweet beverages may work better than eating ... When it comes to losing weight, cutting back on the ... important. , So say researchers who found that cutting back ... per day -- accounted for nearly two-and-a-half pounds of ...
... In a press conference today, Colgate and,the Hispanic ... Salud,Bucal: Un Mundo de Sonrisas Saludables (Oral Health Month: ... commitment to quality oral care among the,Hispanic community. , ... lack of familiarity accessing oral,healthcare services, among other factors, ...
... (Nasdaq: MEDQ ), a leading provider of ... final judgment approving settlement and dismissing the consolidated medical ... of the results of the internal review of its ... about its workforce, and throughout this litigation the Company ...
... Company Reports Earnings per Share of 9 cents ... April 2 Allscripts-Misys Healthcare Solutions, Inc. (Allscripts) ... and nine months ended February 28, 2009. (Logo: ... months ended February 28, 2009 include results of ...
... of a Big Brothers Big Sisters of America ... women mentors, revealed that strong emotional support and ... was a dominant theme coupled with the development ... , Unlike previous mentoring studies, this one explicitly ...
... April 2 Varian Medical Systems (NYSE: ... a mid-year review for investors from noon through 2 p.m. ... hotel located at 1 Avenue De Lafayette. Management presentations ... year 2009, strategic initiatives, and growth opportunities in markets for ...
Cached Medicine News:Health News:Fewer Sugary Drinks Key to Weight Loss 2Health News:Fewer Sugary Drinks Key to Weight Loss 3Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 2Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 3Health News:MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action 2Health News:MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action 3Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 13Health News:Allscripts Reports Fiscal 2009 Third Quarter Results 14Health News:Gaining new insights into mentoring programs for adolescent girls 2Health News:Gaining new insights into mentoring programs for adolescent girls 3Health News:Varian Medical Systems Schedules Mid-Year Review With Investors in Boston 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: